Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer

Author(s):

Bradley Monk, MD,Dana M. Chase, MD, FACOG

Bradley Monk, MD, shares the promising potential of anti-HER2 therapy in cervical cancer and discusses encouraging results from recent trials, emphasizing the importance of testing for HER2 and considering anti-HER2 antibody drug conjugates as a treatment option.

EP: 1.Diagnosing and Staging Patients With Endometrial Cancer

EP: 2.Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

EP: 3.Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

EP: 4.The Role of dMMR in the Progression of Endometrial Cancer

EP: 5.Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

EP: 6.The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

EP: 7.Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

EP: 8.Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

EP: 9.Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

EP: 10.Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

EP: 11.Staging and Biomarker Testing For Patients With Cervical Cancer

EP: 12.Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer

EP: 13.Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

EP: 14.Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs

EP: 15.Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer

Now Viewing